Back to Journals » Cancer Management and Research » Volume 13

The Top 100 Most Frequently Cited Publications Concerning Anti-PD-1/PD-L1 Therapy for Lung Cancer: A Bibliometric Analysis

Authors Li Y, Lv M, Liu J, Ma J, Liang M, Zheng N

Received 8 July 2020

Accepted for publication 28 October 2020

Published 12 February 2021 Volume 2021:13 Pages 1383—1393

DOI https://doi.org/10.2147/CMAR.S270099

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Dr Seema Singh


Yang Li,1 Moyang Lv,2 Jingting Liu,3 Jun Ma,4 Man Liang,5,* Na Zheng6,*

1Department of Thoracic Surgery, The First Hospital of Jilin University, Changchun, People’s Republic of China; 2Grade 2018 Clinical Medicine, Army Medical University, Chongqing, People’s Republic of China; 3Grade 2017 Nursing, Shenzhen University Health Science Center, Shenzhen, People’s Republic of China; 4Department of Radiology, Affiliated Hospital of Beihua University, Jilin, People’s Republic of China; 5Department of Forensic Science, Tongji Medical College, Huazhong University of Science & Technology, Wuhan, People’s Republic of China; 6Department of Pathology, Shenzhen University Health Science Center, Shenzhen, People’s Republic of China

*These authors contributed equally to this work

Correspondence: Man Liang
Department of Forensic Science, Tongji Medical College, Huazhong University of Science & Technology, Wuhan, People’s Republic of China
Email liangman@hust.edu.cn
Na Zheng
Department of Pathology, Shenzhen University Health Science Center, Shenzhen, People’s Republic of China
Email 19629194@qq.com

Background: Globally lung cancer is one of the most common cancers, and is responsible for almost 20% of all cancer care costs. As a potential treatment for lung cancer, anti-PD-1/PD-L1 therapy has become a novel scientific hotspot in recent decades. The present study aims at exploring the status and trends of the top frequently cited publications about the anti-PD-1/PD-L1 therapy for lung cancer via bibliometric analysis.
Methods: The publications concerning anti-PD-1/PD-L1 therapy for lung cancer were searched on the core collection database of Web of Science, setting the time period for retrieval from 1950 to 2019. The top 100 most frequently cited publications were retrieved, and the bibliometric data were mainly accessed through an open online analysis platform and VOSviewer software.
Results: The cited frequencies about the top 100 cited publications ranged from 218 to 6248. These articles were published in 39 publications, which were mainly ranked in Q1. The top journal in terms of the number of the articles was the New England Journal of Medicine (16 articles). The most frequently nominated author was Brahmer, JR from Sidney Kimmel Comprehensive Cancer Center, while the most contributing institution was Memorial Sloan Kettering Cancer. The United States acted as the pioneer in this new field of research and led plentiful of national and international co-operations. Immunotherapy, nivolumab, cell lung-cancer, safety, and docetaxel appeared more frequently as keywords.
Discussions: To sum up, high quality journals, influential authors and institutions and research with high quality evidence were apt to attract more attention and possess more public credibility. Moreover, the bibliometric analysis is yielding up its advantage of identifying and analyzing the characteristics and changes in the intellectual structures of a special topic.

Keywords: anti-PD-1/PD-L1 therapy, bibliometrics, lung cancer, VOSviewer

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]